A roundup of recent financial news including company comparisons, earnings reports, and analyst ratings for firms like Earlyworks, Covestro, Intra-Cellular Therapies, and more. Read more...

Analysts highlight promising stocks across various sectors, including cannabis, blockchain, esports, and industrial materials, offering insights for investors. Read more...

Analyst downgrades and insider selling have sent several stocks tumbling, including Adient, Foot Locker, and ProPetro. Meanwhile, Walmart is drawing attention for positive management changes. Read more...

A roundup of stock analysis reports, comparing companies in the energy and finance sectors, including DraftKings, FTC Solar, and more. Read more...

Recent analyst downgrades have impacted the stock prices of several companies listed on the NYSE, including AES, Dell Technologies, GE Vernova, and Cava Group. This article provides an overview of these changes and their potential implications. Read more...

Recent analyst reports show mixed outlooks for Kimbell Royalty Partners, Sempra, Myriad Genetics, and Okta, with revised price targets and ratings. Read more...

A look at recent investment recommendations, including a robust hold rating for FLRT, a cautious approach for Amprius Technologies, and warnings about YBTC's high-yield risks. Read more...

Chinese manufacturing sees strong growth despite tariff threats, while digital stocks rebound, led by Chinese companies. ITV profits surge on hit shows; Danish postal service ends letter delivery. Read more...

AI stocks like Taiwan Semiconductor and Arista Networks plunge, while analyst ratings for GXO Logistics and Stanley Black & Decker see mixed reviews. BW LPG and others are also analyzed. Read more...

Recent analyst ratings for NYSE-listed companies like PBF Energy, Booz Allen, and Wayfair show a mixed bag of recommendations, from 'Reduce' to 'Moderate Buy'. Stock buybacks and institutional investments are also impacting the market. Read more...

Praxis faces a complex investment landscape. Despite a "Hold" rating and setbacks with Ulixacaltamide, the company presents a high-risk, high-reward opportunity in the epilepsy sector. Read more...

StockNews.com has been busy this week, issuing new ratings on several publicly traded companies. Here's a look at the latest changes and what they mean for investors. Read more...